Back to matchesWe found a matchYour institution may have rights to this item. Sign in to continue.TitleARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?AuthorsKumar, NaveenSubjectsINDIA; ANTIANDROGENS; COMBINATION drug therapy; METASTASIS; TREATMENT duration; TREATMENT effectiveness; DOCETAXEL; SURVIVAL analysis (Biometry); DRUG side effects; PROSTATE tumorsPublicationIndian Journal of Urology, 2022, Vol 38, Issue 3, p238ISSN0970-1591Publication typeArticleDOI10.4103/iju.iju_81_22